Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of HCP1102 in Perennial Allergic Rhinitis
NCT04324918Phase 3Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of montelukast + levocetirizine in perennial allergic rhinitis (PAR), sponsored by Hanmi Pharmaceutical. Started Oct 2018; status: completed.
02
Drugs
montelukast + levocetirizine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT04324918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04324918.